AtriCure Inc. (NASDAQ:ATRC)’s share price traded up 5.3% during mid-day trading on Tuesday . The company traded as high as $16.81 and last traded at $16.73, with a volume of 193,664 shares traded. The stock had previously closed at $15.89.
A number of equities analysts have recently issued reports on the company. Canaccord Genuity set a $21.00 price target on AtriCure and gave the stock a “buy” rating in a research report on Saturday, August 6th. JMP Securities set a $23.00 price target on AtriCure and gave the stock a “buy” rating in a research report on Saturday, August 6th. BTIG Research reissued a “buy” rating and set a $19.00 price target (down previously from $34.00) on shares of AtriCure in a research report on Wednesday, August 10th. Piper Jaffray Cos. reissued an “overweight” rating and set a $17.00 price target (down previously from $22.00) on shares of AtriCure in a research report on Monday, August 8th. Finally, Stifel Nicolaus dropped their price target on AtriCure from $26.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $20.13.
The firm’s market capitalization is $564.10 million. The firm has a 50 day moving average of $14.99 and a 200 day moving average of $15.57.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/atricure-inc-atrc-trading-5-3-higher/
AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. During the same period last year, the business earned ($0.18) earnings per share. The company earned $39.70 million during the quarter, compared to analysts’ expectations of $39.84 million. The company’s revenue for the quarter was up 21.8% compared to the same quarter last year. On average, analysts forecast that AtriCure Inc. will post ($1.16) EPS for the current year.
In other news, Director Elizabeth D. Krell sold 5,000 shares of AtriCure stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $15.20, for a total transaction of $76,000.00. Following the sale, the director now directly owns 15,162 shares of the company’s stock, valued at $230,462.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.